PSA doubling time is a strong predictor of metastases in patients with nmCRPC, which is defined as CRPC with no visible metastatic disease according to conventional imaging. For this group of patients, a PSA doubling time of 10 months or less is associated with a high risk of developing metastatic disease or dying from prostate cancer.
For men with advanced prostate cancer, a blood chemistry profile including serum creatinine level and liver function tests may be useful.
Learn more about mCRPC.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kyle A. Richards. Fast Five Quiz: Castration-Resistant Prostate Cancer - Medscape - Dec 02, 2020.